Friday, November 8, 2019

Biomedical Journal of Scientific & Technical Research Is for the Craving Readers

Although the ISSN entry for the Biomedical Journal of Scientific & Technical Research identifies it as a US publication, its mangled management of the English language suggests otherwise. The website describes the goal of this journal's "publishers" as follows:
The only motto of Biomedical Journal of Scientific & Technical Research (BJSTR) Publishers is accelerating the scientific and technical research papers, considering the importance of technology and the human health in the advanced levels and several emergency medical and clinical issues associated with it, the key attention is given towards biomedical research. Thus, asserting the requirement of a common evoked and enriched information sharing platform for the craving readers.

BJSTR is such a unique platform to accumulate and publicize scientific knowledge on science and related discipline. This multidisciplinary open access publisher is rendering a global podium for the professors, academicians, researchers and students of the relevant disciplines to share their scientific excellence in the form of an original research article, review article, case reports, short communication, e-books, video articles, etc.

BJSTR Publishers are self supporting, with no dependency on any other external sources (like universities, centers) for funds and strives for the best and enhanced quality publications competes the world wide open access publishing market.

We always rely on the support from the members of our BJSTR family that is relevantly our Authors, Editorial Committee members, advisory board, Reviewers Board and all the technical support teams all over the globe. We trust in the reciprocated coordination and cooperation in terms of sharing the scientific knowledge of individuals and Groups of Research centers/areas will in turn educates and provokes in advanced researches. In this case we would like to act as a media that anchors in the transformation of information in the form of global online publication.
With writing like this, the absence of "dependency on any ... external sources (like universities, centers) for fund" is understandable. So is the fact that the journal is not in the National Library of Medicine collection and not indexed for Medline. In fact, when one researcher "submitted a string of machine-generated nonsense" entitled "The Expression of the Proper-Name Effect Reinforces the Disarticulation ofCommunicative [sic] Rationality," the article was "quickly accepted after scrupulous peer review." Evidently, the editors did not notice that the author was Harold E. Potter of the Institute of Improbabilistics, University of Bogus, UK. An author posting on Researchgate reports that when he declined to pay the $600 fee, the journal dropped the price to $99.

Wisely, the publishers do not reveal their identities. The domain name in the email is registered to a privacy service. The contact information on the website is Biomedical Research Network+, LLC, 1 Westbrook Corporate Center, Suite 300, one Westchester, IL 60154, USA +1 (720) 414-3554 Fax - (720) 367-5187 The registrant of provides the same physical address along with the name Biomedical Research Network + LLC and email URL of The Westbrook Corporate Center is a property with "virtual office" space on sale for as little as $2 a day.
From the Editorial office []
Sent: Friday, November 8, 2019 2:35 AM
Subject: Eminent Article Dear Dr. DH Kaye
Dear Dr. DH Kaye,
Start each day with a grateful heart.
The purpose of this email is to inform you that we need your support for releasing our upcoming issue by submitting one article to our Biomedical Journal of Scientific & Technical Research with (ISSN: 2574-1241) Impact Factor 0.548.
Can we expect your article before 19th November? ← I don't think so.
If this is a short notice please do send an opinion or mini review or case report by next weekend, we hope that a minimum of 2-page article isnt time taken for an eminent author like you.
Await your promising response.
Lacey Dickson

1 comment: